Key facts
- TearOptix’s last known valuation is $19.4M (Jan 2023).
- It has raised $4.3M; the latest was Early Stage VC in Nov 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for TearOptix
- ·The full record, as it builds
Funding rounds
No funding rounds for TearOptix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TearOptix
Operator of an adaptive contact lens technology intended to improve vision for individuals experiencing age-related focusing challenges. The company offers tear- and blink-responsive optics, advanced lens engineering, and clinically informed design, enabling eye-care providers and adults with presbyopia, to achieve clearer, comfortable, and natural vision at varying distances.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Menlo Park, CA, United States
- Founded
- 2021
- Ownership
- Privately Held (backing)
TearOptix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TearOptix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TearOptix in its N-PORT filings yet. We sweep new filings monthly.